Cellectis S.A. (CLLS)Healthcare | Biotechnology | Paris, France | NasdaqGM
4.42 USD
+0.15
(3.513%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 4.42 Short-term: ★★☆☆☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:25 p.m. EDT
Despite negative fundamentals and a bearish short-term algorithmic forecast (-1.8%), CLLS is offering a high-risk asymmetry. The market prices in significant upside via Call OI at $5.00 and $7.50, ignoring immediate losses. For the long term, the product pipeline (Allogeneic CAR-T) has generated enough buzz to justify a 'Buy' despite still being in early clinical stages. It remains a speculative hold until profitability is demonstrated, but the options flow suggests smart money disagrees with the short-term bearish technical models. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.144322 |
| AutoARIMA | 0.144325 |
| MSTL | 0.161626 |
| AutoTheta | 0.185071 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 54% |
| H-stat | 2.95 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.443 |
| Excess Kurtosis | -0.92 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 114.216 |
| Revenue per Share | 0.794 |
| Market Cap | 455,539,072 |
| Forward P/E | -7.13 |
| Beta | 2.71 |
| Profit Margins | -84.92% |
| Website | https://www.cellectis.com |
As of April 18, 2026, 11:25 p.m. EDT: Options data shows a distinct asymmetry. Call OI is heavily concentrated above the current price ($3.59 prev close, trading near $4.42 now), specifically at $5.00 and $7.50 strikes across May and August expirations, indicating a bullish rotation cap or bias. Conversely, Put OI is dominated at the $2.50 strike (deep ITM), suggesting a defensive floor play rather than a immediate crash expectation. However, the Short-Term forecast model predicts a -1.82% price move, and the Ljung-Box p-value indicates strong non-randomness in prices, warning of potential mean reversion. The current atmosphere is one of controlled optimism with a defined downside floor.
| Attribute | Value |
|---|---|
| 52 Week Change | 2.2028985 |
| Address1 | 8, rue de la Croix Jarry |
| All Time High | 50.0 |
| All Time Low | 0.963 |
| Ask | 4.31 |
| Ask Size | 1 |
| Average Analyst Rating | 1.8 - Buy |
| Average Daily Volume10 Day | 53,240 |
| Average Daily Volume3 Month | 44,770 |
| Average Volume | 44,770 |
| Average Volume10Days | 53,240 |
| Beta | 2.711 |
| Bid | 4.26 |
| Bid Size | 1 |
| Book Value | 1.049 |
| City | Paris |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | France |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 4.42 |
| Current Ratio | 1.621 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 4.5001 |
| Day Low | 4.36 |
| Debt To Equity | 114.216 |
| Display Name | Cellectis |
| Earnings Call Timestamp End | 1,774,008,000 |
| Earnings Call Timestamp Start | 1,774,008,000 |
| Earnings Timestamp | 1,773,950,400 |
| Earnings Timestamp End | 1,779,134,400 |
| Earnings Timestamp Start | 1,779,134,400 |
| Ebitda | -21,750,000 |
| Ebitda Margins | -0.27327 |
| Enterprise To Ebitda | -9.249 |
| Enterprise To Revenue | 2.527 |
| Enterprise Value | 201,162,192 |
| Eps Forward | -0.62 |
| Eps Trailing Twelve Months | -0.67 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.661 |
| Fifty Day Average Change | 0.75900006 |
| Fifty Day Average Change Percent | 0.20732042 |
| Fifty Two Week Change Percent | 220.28986 |
| Fifty Two Week High | 5.48 |
| Fifty Two Week High Change | -1.06 |
| Fifty Two Week High Change Percent | -0.19343065 |
| Fifty Two Week Low | 1.327 |
| Fifty Two Week Low Change | 3.093 |
| Fifty Two Week Low Change Percent | 2.3308213 |
| Fifty Two Week Range | 1.327 - 5.48 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,427,203,800,000 |
| Float Shares | 46,679,639 |
| Forward Eps | -0.62 |
| Forward P E | -7.129032 |
| Free Cashflow | -25,282,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 224 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 1.0 |
| Gross Profits | 79,593,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.16956 |
| Implied Shares Outstanding | 103,063,132 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France. |
| Long Name | Cellectis S.A. |
| Market | us_market |
| Market Cap | 455,539,072 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1216695 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -67,593,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 448,152,823 |
| Number Of Analyst Opinions | 4 |
| Open | 4.4 |
| Operating Cashflow | -39,401,000 |
| Operating Margins | -1.4214 |
| Payout Ratio | 0.0 |
| Phone | 33 1 81 69 16 00 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 4.42 |
| Post Market Time | 1,776,456,291 |
| Previous Close | 4.27 |
| Price Hint | 4 |
| Price To Book | 4.2135367 |
| Price To Sales Trailing12 Months | 5.723356 |
| Profit Margins | -0.84923 |
| Quick Ratio | 1.59 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.75 |
| Region | US |
| Regular Market Change | 0.15 |
| Regular Market Change Percent | 3.51288 |
| Regular Market Day High | 4.5001 |
| Regular Market Day Low | 4.36 |
| Regular Market Day Range | 4.36 - 4.5001 |
| Regular Market Open | 4.4 |
| Regular Market Previous Close | 4.27 |
| Regular Market Price | 4.42 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 73,077 |
| Return On Assets | -0.058379997 |
| Return On Equity | -0.65328 |
| Revenue Growth | -0.195 |
| Revenue Per Share | 0.794 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 72,590,994 |
| Shares Percent Shares Out | 0.0036000002 |
| Shares Short | 358,609 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 388,537 |
| Short Name | Cellectis S.A. |
| Short Percent Of Float | 0.0064999997 |
| Short Ratio | 6.71 |
| Source Interval | 15 |
| Symbol | CLLS |
| Target High Price | 10.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 7.25 |
| Target Median Price | 7.5 |
| Total Cash | 206,380,992 |
| Total Cash Per Share | 2.843 |
| Total Debt | 86,691,000 |
| Total Revenue | 79,593,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.67 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.55459 |
| Two Hundred Day Average Change | 0.8654101 |
| Two Hundred Day Average Change Percent | 0.2434627 |
| Type Disp | Equity |
| Volume | 73,077 |
| Website | https://www.cellectis.com |
| Zip | 75,013 |